TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effects of Intraoperative Dexamethasone and Ondansetron on Postoperative Nausea and Vomiting in Microvascular Decompression Surgery: A Randomized Controlled Study
Brief Summary: Postoperative nausea and vomiting (PONV) is a common problem and may lead to catastrophic complications, especially in neurosurgical cases. The aim of this study was to evaluate the effects of dexamethasone and ondansetron for preventing PONV in patients who underwent microvascular decompression surgery (MVD).


Options:
A: Arm Label: 8 mg dexamethasone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Dexamethasone | Arm Label: Placebo, saline; Type: PLACEBO_COMPARATOR; Interventions: Drug: Dexamethasone | Arm Label: 40 mg dexamethasone; Type: EXPERIMENTAL; Interventions: Drug: Dexamethasone | Intervention Type: DRUG; Name: Dexamethasone; Assigned to Arm(s): 40 mg dexamethasone, 8 mg dexamethasone, Placebo, saline
B: Arm Label: The study group (Gr. D); Type: EXPERIMENTAL; Interventions: Drug: Dexamethasone, Drug: Ondansetron | Arm Label: the control group (Gr. N); Type: PLACEBO_COMPARATOR; Interventions: Drug: 0.9% Sodium Chloride Injection | Intervention Type: DRUG; Name: Dexamethasone; Assigned to Arm(s): The study group (Gr. D) | Intervention Type: DRUG; Name: Ondansetron; Assigned to Arm(s): The study group (Gr. D) | Intervention Type: DRUG; Name: 0.9% Sodium Chloride Injection; Assigned to Arm(s): the control group (Gr. N)
C: Intervention Type: OTHER; Name: Mild intraoperative hypercapnia (50 mmHg vs. 30 mmHg); Assigned to Arm(s): N/A | Intervention Type: OTHER; Name: Supplemental oxygen (80% vs. 30%); Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Dexamethasone; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): N/A
D: Intervention Type: DRUG; Name: MK0869, aprepitant; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Comparator: ondansetron IV; Assigned to Arm(s): N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomized Evaluation of Beta Blocker and Angiotensin Converting Enzyme Inhibitor (ACEI) /Angiotensin Receptor Blocker (ARB) Treatment in MINOCA Patients.
Brief Summary: Myocardial infarction with non-obstructive coronary arteries" (MINOCA) occurs in 5-10% of all patients with AMI. There are neither any randomized clinical trials in MINOCA patients evaluating effects of secondary preventive treatments proven beneficial in patients with classic AMI, nor any treatment guidelines.

The primary objective of this multi-national, multi-center pragmatic randomized clinical trial is to determine whether oral beta-blockade compared to no oral beta-blockade, and whether Angiotensin Converting Enzyme Inhibitors (ACEI/ Angiotensin Receptor Blockers (ARB) compared to no ACEI/ARB, reduce the composite endpoint of death of any cause and readmission because of AMI, ischemic stroke or heart failure in patients discharged with myocardial infarction with non-obstructive coronary artery disease (MINOCA) and with no clinical signs of heart failure and with left ventricular (LV) systolic ejection fraction ≥40%.


Options:
A: Arm Label: Beta blocker treatment; Type: EXPERIMENTAL; Interventions: Drug: Metoprolol Succinate, Drug: Bisoprolol, Drug: Carvedilol, Drug: Nebivolol | Arm Label: No beta blocker treatment; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Metoprolol Succinate; Assigned to Arm(s): Beta blocker treatment | Intervention Type: DRUG; Name: Bisoprolol; Assigned to Arm(s): Beta blocker treatment | Intervention Type: DRUG; Name: Carvedilol; Assigned to Arm(s): Beta blocker treatment | Intervention Type: DRUG; Name: Nebivolol; Assigned to Arm(s): Beta blocker treatment
B: Arm Label: A; Type: EXPERIMENTAL; Interventions: Drug: Metoprolol controlled release (CR) | Arm Label: B; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Metoprolol controlled release (CR); Assigned to Arm(s): A | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): B
C: Intervention Type: DRUG; Name: clopidogrel and metoprolol; Assigned to Arm(s): N/A
D: Arm Label: No Beta blocker and no ACEI/ARB; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Beta blocker and ACEI/ARB; Type: EXPERIMENTAL; Interventions: Drug: Beta blocker, Drug: ACEI, Drug: ARB | Arm Label: Beta blocker alone; Type: EXPERIMENTAL; Interventions: Drug: Beta blocker | Arm Label: ACEI/ARB alone; Type: EXPERIMENTAL; Interventions: Drug: ACEI, Drug: ARB | Intervention Type: DRUG; Name: Beta blocker; Assigned to Arm(s): Beta blocker alone, Beta blocker and ACEI/ARB | Intervention Type: DRUG; Name: ACEI; Assigned to Arm(s): ACEI/ARB alone, Beta blocker and ACEI/ARB | Intervention Type: DRUG; Name: ARB; Assigned to Arm(s): ACEI/ARB alone, Beta blocker and ACEI/ARB

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: SPIDER: A Structured Process Informed by Data, Evidence and Research - A Research and Quality Improvement Collaboration Supporting Practices in Improving Care for Complex Elderly Patients
Brief Summary: Elders living with multiple chronic conditions often take many drugs (polypharmacy); some of the drugs may not benefit them or may be harmful. The Canadian Institute for Health Information has reported that about one-quarter of Canadian seniors are prescribed ten or more different drugs each year. Polypharmacy can result in poorer health, reduced quality of life and high healthcare costs. Choosing Wisely Canada and the Canadian Deprescribing Network have suggested wiser uses for the following four Potentially Inappropriate Prescriptions (PIPs): drugs that reduce stomach acid; reduce anxiety and induce sleep; treat agitation; and treat type 2 diabetes but have a high risk of low blood sugar. To improve care for elderly patients living with polypharmacy, we propose SPIDER: a Structured Process Informed by Data, Evidence and Research. Using quality improvement (QI) and supported by Electronic Medical Record (EMR) data, SPIDER will invite family doctors, nurses, pharmacists and front desk staff to participate in Learning Collaboratives and learn from each other. The practice teams will work with a QI Coach to identify areas to improve, develop strategies and implement changes tailored to the local practice context. The objective of this study is to determine whether SPIDER will reduce PIPs for patients 65 years or older who are on ten or more different drugs. The study will also explore patient experience and provider satisfaction with SPIDER and assess the cost of running SPIDER. The study will first be tested for feasibility in Toronto, Edmonton and Montreal. Findings will then guide a Randomized Controlled Trial (RCT) in Calgary, Winnipeg, Ottawa, Montreal and Halifax where practices enrolled in the SPIDER intervention will be compared with those in usual care.


Options:
A: Intervention Type: BEHAVIORAL; Name: Self-management of chronic illness; Assigned to Arm(s): N/A
B: Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Other: Deprescribing opportunities | Intervention Type: OTHER; Name: Deprescribing opportunities; Assigned to Arm(s): Intervention
C: Arm Label: SPIDER; Type: EXPERIMENTAL; Interventions: Procedure: SPIDER, Procedure: Usual Care | Arm Label: Usual Care; Type: PLACEBO_COMPARATOR; Interventions: Procedure: Usual Care | Intervention Type: PROCEDURE; Name: SPIDER; Assigned to Arm(s): SPIDER | Intervention Type: PROCEDURE; Name: Usual Care; Assigned to Arm(s): SPIDER, Usual Care
D: Arm Label: Standard care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Other: Interdisciplinary collaboration structure | Intervention Type: OTHER; Name: Interdisciplinary collaboration structure; Assigned to Arm(s): Intervention

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effects of Prebiotic Supplementation and Exercise on Inflammatory Markers, Vascular Function, Cognition, and Mental Well-being in Pre-Dialysis Kidney Patients
Brief Summary: The study is primarily designed to examine the effect of 16 weeks of prebiotic supplementation (resistant starch)and moderate intensity aerobic training on markers of inflammation in stage 3-4 patients with chronic kidney disease.


Options:
A: Arm Label: probiotic soy milk; Type: EXPERIMENTAL; Interventions: Dietary Supplement: probiotic soy milk | Arm Label: soy milk; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: probiotic soy milk | Intervention Type: DIETARY_SUPPLEMENT; Name: probiotic soy milk; Assigned to Arm(s): probiotic soy milk, soy milk
B: Arm Label: Exercise; Type: EXPERIMENTAL; Interventions: Behavioral: Exercise | Arm Label: Resistant Starch; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Resistant starch | Arm Label: Exercise & Resistant Starch; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Resistant starch, Behavioral: Exercise | Arm Label: Starch; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Starch | Intervention Type: DIETARY_SUPPLEMENT; Name: Resistant starch; Assigned to Arm(s): Exercise & Resistant Starch, Resistant Starch | Intervention Type: BEHAVIORAL; Name: Exercise; Assigned to Arm(s): Exercise, Exercise & Resistant Starch | Intervention Type: BEHAVIORAL; Name: Starch; Assigned to Arm(s): Starch
C: Arm Label: Corn Starch; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Corn starch | Arm Label: Fiber; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Fiber | Intervention Type: DIETARY_SUPPLEMENT; Name: Fiber; Assigned to Arm(s): Fiber | Intervention Type: DIETARY_SUPPLEMENT; Name: Corn starch; Assigned to Arm(s): Corn Starch
D: Arm Label: Probiotics; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Probiotics | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Probiotics | Intervention Type: DIETARY_SUPPLEMENT; Name: Probiotics; Assigned to Arm(s): Placebo, Probiotics

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effects of Interactive Video Game-based Exercise on Balance of Persons With Parkinson's Disease
Brief Summary: This study assessed the effects of interactive video game-based exercise (IVGB) on balance in persons with Parkinson's disease . Twenty-four patients were randomly allocated to two groups (12 participants per group). Group A underwent IVGB training for the first 6 weeks, with no exercise in the subsequent 6 weeks. Group B had no exercise for the first 6 weeks and then received IVGB training in the subsequent 6 weeks. Both subjective and objective measures were used to determine whether IVGB exercise improves balance function.


Options:
A: Arm Label: Physical Therapy; Type: EXPERIMENTAL; Interventions: Behavioral: Physical Therapy | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Physical Therapy; Assigned to Arm(s): Physical Therapy
B: Arm Label: Group A; Type: EXPERIMENTAL; Interventions: Other: interactive video game-based exercise, Other: no intervention | Arm Label: Group B; Type: EXPERIMENTAL; Interventions: Other: interactive video game-based exercise, Other: no intervention | Intervention Type: OTHER; Name: interactive video game-based exercise; Assigned to Arm(s): Group A, Group B | Intervention Type: OTHER; Name: no intervention; Assigned to Arm(s): Group A, Group B
C: Arm Label: Tai Chi; Type: EXPERIMENTAL; Interventions: Behavioral: Tai Chi | Arm Label: B. Strength training; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Strength training | Arm Label: C. Low-Impact; Type: OTHER; Interventions: Behavioral: Low-Impact Exercise Control | Intervention Type: BEHAVIORAL; Name: Tai Chi; Assigned to Arm(s): Tai Chi | Intervention Type: BEHAVIORAL; Name: Strength training; Assigned to Arm(s): B. Strength training | Intervention Type: BEHAVIORAL; Name: Low-Impact Exercise Control; Assigned to Arm(s): C. Low-Impact
D: Arm Label: Group B; Type: PLACEBO_COMPARATOR; Interventions: Device: Libra Deep Brain Stimulation System | Arm Label: Group A; Type: EXPERIMENTAL; Interventions: Device: Libra Deep Brain Stimulation System | Intervention Type: DEVICE; Name: Libra Deep Brain Stimulation System; Assigned to Arm(s): Group A | Intervention Type: DEVICE; Name: Libra Deep Brain Stimulation System; Assigned to Arm(s): Group B

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Low-dose Atropine Eye Drops to Reduce Progression of Myopia in Children: a Multi-centre Placebo Controlled Randomised Trial in the United Kingdom
Brief Summary: Short-sightedness, also called myopia, makes objects in the distance, such as the television, look blurred. This is caused by the eye growing too long, something that usually happens while children are also getting taller. People with myopia can see better with glasses or contact lenses, but this doesn't stop their eyes continuing to become more short-sighted. The CHAMP UK study is investigating a type of eye drop called atropine that might help to stop myopia getting worse as children get older.


Options:
A: Intervention Type: DEVICE; Name: Polymethyl Methacrylate-Silicone Contact Lenses; Assigned to Arm(s): N/A | Intervention Type: DEVICE; Name: Polymethyl Methacrylate Contact Lenses; Assigned to Arm(s): N/A
B: Intervention Type: DRUG; Name: Atropine Eye drops; Assigned to Arm(s): N/A
C: Arm Label: Intervention Group (Atropine 0.01%); Type: EXPERIMENTAL; Interventions: Drug: Atropine Sulfate | Arm Label: Placebo Group; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: Atropine Sulfate; Assigned to Arm(s): Intervention Group (Atropine 0.01%) | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo Group
D: Arm Label: ortho-k and 0.01% atropine eye drops; Type: EXPERIMENTAL; Interventions: Drug: 0.01% atropine eye drops, Device: ortho-k | Arm Label: ortho-k; Type: ACTIVE_COMPARATOR; Interventions: Device: ortho-k | Intervention Type: DRUG; Name: 0.01% atropine eye drops; Assigned to Arm(s): ortho-k and 0.01% atropine eye drops | Intervention Type: DEVICE; Name: ortho-k; Assigned to Arm(s): ortho-k, ortho-k and 0.01% atropine eye drops

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Impact of Cardiovascular Rehabilitation on the Quality of Life of Adolescents and Young Adults With Congenital Heart Disease: A Randomized Controlled Multicentre Trial
Brief Summary: The investigators aim to measure the impact of a rehabilitation program in congenital cardiology in terms of health related quality of life. The orginality of the rehabilitation program consists in its design : initial hospitalizationfor a short period of time (5 days) at the rehabilitation center, followed by 11 weeks of rehabilitation at home under the supervision of a specialized sports trainer.


Options:
A: Arm Label: Fitbit Only; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Physical Activity Monitoring | Arm Label: Fitbit + Coaching Sessions; Type: EXPERIMENTAL; Interventions: Behavioral: Physical Activity Lifestyle Intervention, Behavioral: Physical Activity Monitoring | Intervention Type: BEHAVIORAL; Name: Physical Activity Lifestyle Intervention; Assigned to Arm(s): Fitbit + Coaching Sessions | Intervention Type: BEHAVIORAL; Name: Physical Activity Monitoring; Assigned to Arm(s): Fitbit + Coaching Sessions, Fitbit Only
B: Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Rehabilitaiton; Type: ACTIVE_COMPARATOR; Interventions: Other: Cardiac rehabilitation | Intervention Type: OTHER; Name: Cardiac rehabilitation; Assigned to Arm(s): Rehabilitaiton
C: Arm Label: Control group; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: One active intervention group; Type: EXPERIMENTAL; Interventions: Behavioral: an mHealth intervention | Arm Label: The other active intervention group; Type: EXPERIMENTAL; Interventions: Behavioral: an mHealth intervention | Intervention Type: BEHAVIORAL; Name: an mHealth intervention; Assigned to Arm(s): One active intervention group, The other active intervention group
D: Arm Label: Aerobic training only; Type: EXPERIMENTAL; Interventions: Behavioral: Exercise training | Arm Label: Combined aerobic and strength training; Type: EXPERIMENTAL; Interventions: Behavioral: Exercise training | Intervention Type: BEHAVIORAL; Name: Exercise training; Assigned to Arm(s): Aerobic training only, Combined aerobic and strength training

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Improving Medication Adherence in Adolescents Who Had a Liver Transplant
Brief Summary: The study's aim is to test a tailored telemetric intervention to reduce rejection incidence by improving medication adherence in a group of adolescent liver transplant recipients identified as nonadherent by a marker (the Medication Level Variability Index, MLVI).


Options:
A: Arm Label: Patient education program; Type: EXPERIMENTAL; Interventions: Behavioral: Patient education program | Arm Label: Standard care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Patient education program; Assigned to Arm(s): Patient education program
B: Arm Label: Telemetric Intervention Arm; Type: EXPERIMENTAL; Interventions: Behavioral: Telemetric Intervention | Arm Label: Standard of Care Arm; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Telemetric Intervention; Assigned to Arm(s): Telemetric Intervention Arm
C: Arm Label: Tacrolimus + MMF; Type: ACTIVE_COMPARATOR; Interventions: Drug: Tacrolimus, Drug: Prednisone, Drug: Mycophenolate mofetil | Arm Label: Envarsus + Everolimus; Type: ACTIVE_COMPARATOR; Interventions: Drug: Tacrolimus, Drug: Prednisone, Drug: Everolimus | Intervention Type: DRUG; Name: Tacrolimus; Assigned to Arm(s): Envarsus + Everolimus, Tacrolimus + MMF | Intervention Type: DRUG; Name: Prednisone; Assigned to Arm(s): Envarsus + Everolimus, Tacrolimus + MMF | Intervention Type: DRUG; Name: Mycophenolate mofetil; Assigned to Arm(s): Tacrolimus + MMF | Intervention Type: DRUG; Name: Everolimus; Assigned to Arm(s): Envarsus + Everolimus
D: Arm Label: Tacrolimus twice-daily; Type: ACTIVE_COMPARATOR; Interventions: Drug: Tacrolimus twice daily | Arm Label: Envarsus XR; Type: ACTIVE_COMPARATOR; Interventions: Drug: Envarsus XR | Intervention Type: DRUG; Name: Envarsus XR; Assigned to Arm(s): Envarsus XR | Intervention Type: DRUG; Name: Tacrolimus twice daily; Assigned to Arm(s): Tacrolimus twice-daily

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Comparative Effectiveness Trial of Transoral Head and Neck Surgery Followed by Adjuvant Radio(Chemo)Therapy Versus Primary Radiochemotherapy for Oropharyngeal Cancer
Brief Summary: Comparative Effectiveness Trial of Transoral Head and Neck Surgery followed by adjuvant Radio(chemo)therapy versus primary Radiochemotherapy for Oropharyngeal Cancer


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Procedure: Selective neck dissection | Arm Label: 2; Type: OTHER; Interventions: Procedure: Conventional Neck dissection | Intervention Type: PROCEDURE; Name: Selective neck dissection; Assigned to Arm(s): 1 | Intervention Type: PROCEDURE; Name: Conventional Neck dissection; Assigned to Arm(s): 2
B: Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Fluorescence visualization device | Arm Label: B; Type: EXPERIMENTAL; Interventions: Procedure: Fluorescence visualization device | Intervention Type: PROCEDURE; Name: Fluorescence visualization device; Assigned to Arm(s): B | Intervention Type: PROCEDURE; Name: Fluorescence visualization device; Assigned to Arm(s): A
C: Arm Label: Resection/adjuvant radio(-chemo)therapy; Type: EXPERIMENTAL; Interventions: Procedure: Resection, Radiation: Radiotherapy, Drug: Chemotherapy | Arm Label: Adjuvant radio(-chemo)therapy/salvage neck dissection; Type: ACTIVE_COMPARATOR; Interventions: Radiation: Radiotherapy, Drug: Chemotherapy, Procedure: Salvage neck dissection | Intervention Type: PROCEDURE; Name: Resection; Assigned to Arm(s): Resection/adjuvant radio(-chemo)therapy | Intervention Type: RADIATION; Name: Radiotherapy; Assigned to Arm(s): Adjuvant radio(-chemo)therapy/salvage neck dissection, Resection/adjuvant radio(-chemo)therapy | Intervention Type: DRUG; Name: Chemotherapy; Assigned to Arm(s): Adjuvant radio(-chemo)therapy/salvage neck dissection, Resection/adjuvant radio(-chemo)therapy | Intervention Type: PROCEDURE; Name: Salvage neck dissection; Assigned to Arm(s): Adjuvant radio(-chemo)therapy/salvage neck dissection
D: Arm Label: harmonic scalpel; Type: EXPERIMENTAL; Interventions: Procedure: surgical resection | Arm Label: standard technique; Type: ACTIVE_COMPARATOR; Interventions: Procedure: surgical resection | Intervention Type: PROCEDURE; Name: surgical resection; Assigned to Arm(s): harmonic scalpel, standard technique

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3 Study Evaluating the Pharmacokinetics, Safety, and Tolerability of VX-445/TEZ/IVA Triple Combination Therapy in Cystic Fibrosis Subjects 6 Through 11 Years of Age
Brief Summary: This study will evaluate the pharmacokinetics (PK), safety, tolerability, efficacy, and pharmacodynamic effect of VX-445, tezacaftor (TEZ), and ivacaftor (IVA) when dosed in triple combination (TC) in Cystic Fibrosis (CF) subjects 6 through 11 years of age with F/F and F/MF genotypes.


Options:
A: Arm Label: Part A; Type: EXPERIMENTAL; Interventions: Drug: lumacaftor, Drug: ivacaftor | Arm Label: Part B; Type: EXPERIMENTAL; Interventions: Drug: lumacaftor, Drug: ivacaftor | Intervention Type: DRUG; Name: lumacaftor; Assigned to Arm(s): Part A, Part B | Intervention Type: DRUG; Name: ivacaftor; Assigned to Arm(s): Part A, Part B
B: Arm Label: ELX/TEZ/IVA; Type: EXPERIMENTAL; Interventions: Drug: ELX/TEZ/IVA, Drug: IVA | Intervention Type: DRUG; Name: ELX/TEZ/IVA; Assigned to Arm(s): ELX/TEZ/IVA | Intervention Type: DRUG; Name: IVA; Assigned to Arm(s): ELX/TEZ/IVA
C: Arm Label: Part A: ELX/TEZ/IVA; Type: EXPERIMENTAL; Interventions: Drug: ELX/TEZ/IVA, Drug: IVA | Arm Label: Part B: ELX/TEZ/IVA; Type: EXPERIMENTAL; Interventions: Drug: ELX/TEZ/IVA, Drug: IVA | Intervention Type: DRUG; Name: ELX/TEZ/IVA; Assigned to Arm(s): Part A: ELX/TEZ/IVA, Part B: ELX/TEZ/IVA | Intervention Type: DRUG; Name: IVA; Assigned to Arm(s): Part A: ELX/TEZ/IVA, Part B: ELX/TEZ/IVA
D: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: LUM 600 mg qd/IVA 250 mg q12h; Type: EXPERIMENTAL; Interventions: Drug: Lumacaftor Plus Ivacaftor Combination, Drug: Ivacaftor | Arm Label: LUM 400 mg q12h/ IVA 250 mg q12h; Type: EXPERIMENTAL; Interventions: Drug: Lumacaftor Plus Ivacaftor Combination | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Lumacaftor Plus Ivacaftor Combination; Assigned to Arm(s): LUM 400 mg q12h/ IVA 250 mg q12h, LUM 600 mg qd/IVA 250 mg q12h | Intervention Type: DRUG; Name: Ivacaftor; Assigned to Arm(s): LUM 600 mg qd/IVA 250 mg q12h

Answer: C